Silk Road Medical Inc. (SILK) Prelim. Q3 Revenue Misses Consensus

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced preliminary revenue for the quarter ended September 30, 2023, and provided an update to full year 2023 revenue guidance.

Preliminary Third Quarter 2023 Revenue

Preliminary, unaudited third quarter 2023 revenue is expected to be approximately $44.4 million, an increase of 19% as compared to the prior year period.

2023 Financial Guidance

Silk Road Medical now projects revenue for the full year 2023 to range from $170 million to $174 million, which represents 23% to 26% growth over the Company’s prior year revenue.

(Consensus sees Q3 revenue of $46 million and FY revenue of $182 million)

You May Also Be Interested In

• Vishay launches two common mode chokes for automotive and industrial use
• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Nasdaq grants Snail Games conditional listing extension for SNAL stock